Pre-clinical characterization of Dacomitinib (PF-00299804), an irreversible pan-ErbB inhibitor, combined with ionizing radiation for head and neck squamous cell carcinoma.

Epidermal growth factor receptor (EGFR) is over-expressed in nearly all cases of squamous cell carcinoma of the head and neck (SCCHN), and is an important driver of disease progression. EGFR targeted therapies have demonstrated clinical benefit for SCCHN treatment. In this report, we investigated th...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Justin P Williams, Inki Kim, Emma Ito, Wei Shi, Shijun Yue, Lillian L Siu, John Waldron, Brian O'Sullivan, Kenneth W Yip, Fei-Fei Liu
Format: Artigo
Langue:Inglês
Publié: Public Library of Science (PLoS) 2014-01-01
Collection:PLoS ONE
Accès en ligne:http://europepmc.org/articles/PMC4031184?pdf=render
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires